Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

NCT07682961 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

590

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Lenacapavir
DRUG: Lenacapavir Tablet
DRUG: Teropavimab
DRUG: Zinlirvimab
DRUG: Cabotegravir
DRUG: Rilpivirine

Sponsor

Gilead Sciences